PEDIATRICS Vol. 74 No. 2 August 1984, pp. 290-291
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HILGARTNER, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HILGARTNER, M. W.

Complications of Therapy in Hemophilia

MARGARET W. HILGARTNER MD1

1 Department of Pediatrics, Regional Comprehensive Hemophilia Diagnostic and Treatment Center, Cornell University Medical Center, New York

Achievement of hemostasis in patients with hemophilia who develop an inhibitor is known to be much more difficult than in the patient without an inhibitor although the frequency of bleeding is usually not increased. The introduction of prothrombin complex concentrates (PCC) and the activated prothrombin complex concentrates (APCC) containing an inhibitor bypassing activity afford a treatment modality that has been useful in some patients.1,2 However, clinical experience has shown that these concentrates are not as effective in patients with inhibitors as factor VIII concentrates are in patients without inhibitors. The lack of efficacy has resulted in escalation of dose and frequency of administration by physicians, particularly when using the currently available PCC.